Nurix Therapeutics, Inc. NRIX Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months) at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (>=12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (>=12 months)?
- Nurix Therapeutics, Inc. (NRIX) reported available-for-sale debt securities - unrealized loss position (>=12 months) of 0 in Q4 2025.
- What does available-for-sale debt securities - unrealized loss position (>=12 months) mean?
- This captures the fair value of available-for-sale debt securities that have remained in an unrealized loss position for 12 months or more. Persistent unrealized losses may indicate credit quality concerns or structural shifts in interest rates. Investors monitor this to evaluate the risk of potential future write-downs.